Budesonide Inhaler Market

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. For instance, on May 11, 2022, according to the World Health Organization (WHO), Asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children globally. Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths globally. Most asthma-related deaths occur in low- and lower-middle-income countries such as India and Bangladesh, where under-diagnosis and under-treatment is a challenge.

Market Dynamics

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1,000 deaths every day and affects as many as 339 million people worldwide.

Increasing product launch by the key market player in expected to boost the growth of global budesonide inhaler market over the forecast period. For instance, in November 2019, Lupin, Pharmaceutical Company, announced the launch of device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases. The device helped the patients track their metered-dose inhalers (MDI) usage and facilitate improved adherence to therapy. The inhalers are the treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Key features of the study

This report provides an in-depth analysis of the global budesonide inhaler market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global budesonide inhaler market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global budesonide inhaler market.
Budesonide Inhaler Market Segmentation

By Product Type Insights (Revenue, USD Mn, 2020 - 2033)

• Inhalants
• Nebulizer

By Dosage Form Insights (Revenue, USD Mn, 2020 - 2033)

• Aerosols
• Dry Powder
• Suspension
• Sprays

By Strength Insights (Revenue, USD Mn, 2020 - 2033)

• 0.25mg
• 0.5mg
• 1.0mg

By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region Insights (Revenue, USD Mn, 2020 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa
• GCC Countries
• Israel
• Rest of Middle East & Africa

Key Players

• Pfizer Inc.
• Cipla Limited
• Lupin Limited
• Cosmo Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Manus Aktteva Biopharma LLP
• Abbott Laboratories
• Lunan Better Pharmaceutical
• Novartis International AG (Sandoz)
• Mylan N.V.
• Skyepharma
• AstraZeneca Plc.
• Chiesi Farmaceutici S.p.A
• Orion Corporation
• Santarus Inc.
• Synmosa Biopharma Corporation
• Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Show more